Industry-leading Medicare navigation platform Chapter has raised $75 million in Series D funding led by Stripes, with participation from all major investors: XYZ Venture...
Auradine, Inc., a leader in breakthrough, energy-efficient solutions for blockchain and AI infrastructure, today announced closing of an additional $153 million in connection with...
Loti AI has raises $16.2M Series A funding led by Khosla Ventures with additional investments from FUSE, Bling Capital, and Ensemble.
With this round of...
Fourier, a hydrogen production systems company based in Palo Alto, California, has raised $18.5 million in Series A funding.
The round was led by Airbus...
ConductorAI, a pioneering dual-use software company specializing in AI-enabled approvals, today announced $15 million in Series A funding led by Lux Capital with participation...
Today, the AI decision science startup, Bridgetown Research announced $19 million in Series A funding led by Lightspeed and Accel, with participation from a leading research university.
Edera, the pioneer of strong workload isolation technology, announced $15 mn in Series A funding led by M12, Microsoft's Venture Fund, with participation from Mantis VC and In-Q-Tel (IQT). Existing investors Eniac Ventures, 645 Ventures, FPV Ventures, Precursor Ventures, and Rosecliff Ventures also participated in the round.
Hightouch, the leading data and AI platform for marketing and personalization, announced that it has raised an $80 million Series C at a valuation of $1.2 billion. The round was led by Rajeev Dham at Sapphire Ventures, with participation from NVC, ICONIQ Growth, Amplify Partners, Bain Capital Ventures, and Y Combinator.
Abridge, the leading generative AI platform for clinical conversations, has raised a $250 million Series D investment, coinciding with the milestone of surpassing 100 deployments at some of the largest and most complex health systems in the United States.
Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, announced the closing of a $200 million Series C financing led by New Enterprise Associates (NEA) with Foresite Capital joining the round and participation of existing investors including RA Capital Management, Bain Capital Life Sciences, Redmile Group, Samsara BioCapital, Sanofi Ventures, Pontifax, Mass General Brigham Ventures, New Leaf Ventures, funds managed by abrdn Inc., funds and accounts managed by BlackRock, Eurofarma Ventures, and Soleus Capital.
